SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

September 28, 2010 08:45 ET

Radient Pharmaceuticals Signs 5-Year Exclusive Distribution Agreement for Its Onko-Sure Cancer Test in Vietnam, Cambodia, and Laos

TUSTIN, CA--(Marketwire - September 28, 2010) -  Through its subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic (IVD) cancer tests, announced today it has entered into an exclusive 5-year full-service distribution agreement with Phu Gia Trading Co. Ltd. to expand the Company's Onko-Sure™ IVD cancer test into the Vietnam, Laos, and Cambodia healthcare markets.

Phu Gia has committed to purchase a minimum of 2,425 Onko-Sure™ kits over the duration of the agreement.  Phu Gia Trading Co. Ltd. will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure in diagnostic centers and clinical labs throughout the designated territory. Marketing, sales and distribution services include developing product localization strategies; representing Radient Pharmaceuticals and its Onko-Sure IVD cancer test at relevant healthcare conferences and events; and ensuring all relevant product marketing materials are available in local languages. The Phu Gia customer service team will also be responsible for responding to customer inquiries and technical questions. Phu Gia will work directly with the Vietnam Ministry of Health and other government officials to secure approvals and regulatory clearances.   

"Our full-service distribution partnership with Radient allows us to work closely with top diagnostic centers and clinical labs in Vietnam, and reach healthcare professionals across the designated territories of Vietnam, Cambodia and Laos. Cancer continues to be one of our gravest healthcare challenges and Onko-Sure offers a valuable new tool for cancer detection and cancer treatment monitoring," commented Jack Nguyen, President, Phu Gia. "We plan to commit extensive outreach resources to oncology thought leaders along with automating the Onko-Sure test at top labs -- including the Ho Chi Minh Diagnostic Centre, to increase cancer testing across our region."

"With a significant cancer challenge, Asia continues to show an increased demand for cancer diagnostic products like Onko-Sure," commented Mr. Douglas MacLellan, Executive Chairman and CEO of RPC. "Phu Gia becomes our third distribution partner for Onko-Sure in the rapidly expanding Asia healthcare market, and we feel confident in our ability to gain strong market share throughout the region as we establish long-term agreements with well positioned partners like Phu Gia."

Onko‐Sure is a simple, non‐invasive, patent‐pending and regulatory‐approved in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko‐Sure is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada for lung cancer detection and treatment monitoring. 

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at For Investor Relations information contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical's current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel : ) 206.310.5323